Report Highlights

How the biomarker market in the United States works: Supply Chain Explained

The U.S. biomarker supply chain originates in upstream biological sample collection — blood, tissue, urine, and cerebrospinal fluid — sourced from clinical trial networks, biobanks such as the National Cancer Institute's TCGA program, and hospital systems. These biological inputs feed into analytical instrument platforms manufactured primarily by Thermo Fisher Scientific and Illumina in domestic facilities, with critical reagent chemicals — including fluorescent dyes, oligonucleotide primers, and antibody conjugates — sourced from specialty chemical suppliers in the U.S., Germany, and Japan. Processing occurs across three distinct stages: biomarker discovery using high-throughput sequencing or mass spectrometry, validation in CLIA-certified contract laboratories, and clinical-grade assay manufacturing for IVD or companion diagnostic use.

Finished biomarker products and services reach end customers — pharmaceutical companies, hospital laboratories, and clinical research organizations — through direct sales forces for capital equipment, and through specialty distributors such as VWR and Cardinal Health for consumables and kits. Typical lead times from assay development to clinical deployment span 18 to 36 months. Pricing mechanisms are stage-dependent: research-use reagents are competitively bid at low margin, while FDA-cleared companion diagnostics command premium prices negotiated directly with pharma partners. Margin concentrates at the companion diagnostic and data analytics layers, where intellectual property and regulatory clearance create defensible pricing power unavailable at the raw reagent or instrument tier.

Biomarker market dynamics in the United States

The U.S. biomarker market operates under a dual-track pricing structure that sharply differentiates research-use-only products from regulated in vitro diagnostic applications. Research-use reagents and kits are highly commoditized, with intense price competition among Thermo Fisher Scientific, Merck KGaA's MilliporeSigma division, and Bio-Rad Laboratories compressing gross margins below 40% in high-volume categories. Companion diagnostics and FDA-cleared clinical assays, by contrast, are structured around long-term co-development agreements between diagnostics manufacturers and pharmaceutical sponsors, with pricing embedded in drug approval pathways and largely insulated from standard procurement negotiation cycles.

Buyer power is bifurcated: large integrated pharmaceutical companies such as Pfizer and Merck exercise significant negotiating leverage over reagent suppliers but depend on single-source instrument platforms for critical discovery workflows, shifting power back toward platform vendors. Information asymmetry is pronounced in the biomarker validation segment, where CROs possessing proprietary reference datasets and validated assay panels command a 25-35% premium over commodity testing providers. Contracting is increasingly structured as multi-year, milestone-linked agreements rather than spot purchasing, reflecting buyers' need for supply continuity across multi-phase clinical programs.

Growth drivers fuelling biomarker expansion across the United States

Personalized medicine mandates embedded in oncology drug development are the single largest demand driver, directly translating into increased procurement of companion diagnostic development services, tissue-based biomarker panels, and patient stratification platforms. The FDA's 2023 guidance requiring biomarker-driven patient selection for a broader class of oncology NDAs has converted previously optional biomarker programs into regulatory prerequisites, expanding addressable spend per drug development program. This increases upstream demand for next-generation sequencing reagents, antibody arrays, and bioinformatics software capable of generating FDA-submittable biomarker qualification packages — all of which flow through U.S.-based CRO and CDO infrastructure.

Expansion of multi-omics platforms and artificial intelligence-enabled data integration represents the second major growth driver, creating new demand for high-dimensional data generation tools — including single-cell proteomics instruments and spatial transcriptomics systems — that did not exist as commercial product categories five years ago. The third driver is clinical trial volume growth: ClinicalTrials.gov data shows a 31% increase in biomarker-stratified U.S. trial registrations between 2020 and 2024, each trial representing a discrete demand node for sample processing, assay kits, and analytical services across the full supply chain from collection to reporting.

Supply chain risks and market restraints in U.S. biomarkers

Geographic concentration of critical reagent inputs represents the most structurally significant supply chain risk. Oligonucleotide synthesis capacity critical for PCR-based and sequencing biomarker assays is heavily concentrated in three U.S. contract manufacturers — Integrated DNA Technologies, Twist Bioscience, and Agilent Technologies — creating single-source dependency risks for assay developers who cannot easily qualify alternative suppliers within regulatory timelines. Specialty optical components for flow cytometry and imaging platforms depend on Japanese and German precision optics manufacturers, with typical lead times of 16 to 24 weeks that leave instrument manufacturers exposed to demand spikes and logistics disruptions simultaneously.

Regulatory and reimbursement restraints sit at the clinical deployment stage of the supply chain and suppress commercial velocity for validated biomarkers. CMS Local Coverage Determinations for molecular diagnostic tests remained unresolved for an average of 28 months in 2023-2024, creating a financing gap between FDA clearance and commercial revenue realization that disproportionately affects smaller biomarker companies without pharma partnership income. Additionally, GDPR-equivalent state-level data privacy regulations — particularly California's CMIA amendments — impose compliance costs on biomarker database operators that reduce the commercial value of large patient biomarker registries assembled for validation studies.

Where biomarker growth opportunities are emerging in the United States

Decentralized biomarker testing enabled by microfluidic point-of-care platforms represents the most structurally significant near-term opportunity, reconfiguring sample flow away from centralized reference laboratories toward hospital bedsides and outpatient settings. Companies developing sample-to-answer cartridge systems — including Abbott's Alinity platform and emerging microfluidic startups — capture value at both the instrument and high-margin consumable cartridge layers. This reconfiguration compresses supply chain length, reduces cold-chain logistics dependency, and opens reimbursement pathways under hospital-based billing codes that carry higher average selling prices than laboratory-billed codes.

Neurological disease biomarkers represent an underpenetrated application segment, driven by FDA's 2023 accelerated approval of Alzheimer's therapies tied to amyloid-PET and CSF biomarker confirmation. This creates immediate demand for validated immunoassay platforms capable of quantifying phosphorylated tau and neurofilament light chain in clinical laboratory settings — a manufacturing gap not yet filled by major IVD suppliers. Supply chain value in this segment concentrates at the antibody clone development and assay calibration stages, where reference material producers such as the National Institute of Standards and Technology's biomarker reference program provide critical certification infrastructure supporting commercial assay adoption.

Market at a Glance

Regional supply and demand map for U.S. biomarkers

On the supply side, biomarker instrument manufacturing and reagent production is concentrated in the Northeast and West Coast. Thermo Fisher Scientific's primary U.S. manufacturing sites operate in Waltham, Massachusetts and San Diego, California; Illumina manufactures sequencing consumables in San Diego; Bio-Rad's reagent production anchors in Hercules, California. Specialized antibody manufacturing for biomarker assays is clustered in the Boston-Cambridge biotech corridor and Research Triangle Park, North Carolina, where contract biologics manufacturers supply both commercial and clinical-grade antibody panels. Biobank infrastructure supporting validation studies is distributed across NIH-affiliated academic medical centers, with the Mayo Clinic and Johns Hopkins operating the largest sample repositories.

Demand concentrates in states with high clinical trial and pharmaceutical development activity: Massachusetts, California, New Jersey, and North Carolina collectively account for an estimated 62% of U.S. biomarker service procurement. Trade flow imbalances are modest given domestic production strength, but the United States imports specialized reference standards and certified calibrators from European suppliers — particularly from Germany's Roche Diagnostics manufacturing network and Sweden's Olink Proteomics — creating import dependency for high-stakes assay calibration components that cannot be domestically sourced at equivalent quality certification levels. This import reliance introduces lead time and currency risk into the clinical-grade supply layer.

Leading Market Participants

• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories
• Illumina
• Guardant Health
• Myriad Genetics
• Agilent Technologies
• Quanterix Corporation
• Luminex Corporation (DiaSorin)

Long-term biomarker market outlook through 2034

By 2034, the U.S. biomarker supply chain will be structurally reorganized around three shifts: AI-integrated biomarker discovery platforms that compress validation timelines from years to months, spatial multi-omics instrumentation that displaces conventional single-analyte assays in oncology and neurology, and regulatory consolidation that mandates companion diagnostics for a significantly expanded universe of drug approvals. Manufacturing will shift toward modular, software-defined analytical platforms that allow rapid assay reconfiguration — reducing capital expenditure barriers for hospital laboratories seeking to bring biomarker testing in-house rather than outsourcing to central reference labs.

The highest-value supply chain positions in 2034 will be biomarker data platform operators controlling validated reference datasets used for AI model training, and manufacturers of next-generation protein quantification instruments capable of single-molecule sensitivity. Illumina's position in sequencing and Thermo Fisher's integrated reagent-instrument ecosystem position both to maintain platform dominance, but the most significant competitive shifts will come from specialized proteomics and spatial biology companies — particularly 10x Genomics in spatial transcriptomics and Seer Bio in proteomics sample preparation — that are building proprietary workflow lock-in before the market's next consolidation phase.